Gelatin nanocarriers as potential vectors for effective management of tuberculosis

International Journal of Pharmaceutics

Volumn 385, Issue 1-2, 2010, Pages 143-149

  Saraogi, Gaurav Kant ^a   Gupta, Puspa ^b   Gupta, U D ^b   Jain, N K ^a   Agrawal, G P ^a  

^a DR H S GOUR UNIVERSITY   (India)

^b NATIONAL JALMA INSTITUTE FOR LEPROSY AND OTHER MYCOBACTERIAL DISEASES   (India)

Author keywords

Drug delivery; Gelatin nanoparticles; Nanoparticles; Rifampicin; Tuberculosis

Indexed keywords

ACETONE; GELATIN; GLUTARALDEHYDE; NANOCARRIER; NANOPARTICLE; PHOSPHATE BUFFERED SALINE; RIFAMPICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ATOMIC FORCE MICROSCOPY; BACTERIAL COUNT; CONTROLLED STUDY; CYTOTOXICITY; DISPERSION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG RELEASE; DRUG SAFETY; DRUG TARGETING; ENCAPSULATION; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT OUTCOME; TUBERCULOSIS; ULTRAVIOLET SPECTROSCOPY; ZETA POTENTIAL;

ACETONE; ADMINISTRATION, ORAL; ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; AREA UNDER CURVE; CELL LINE; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; GELATIN; INJECTIONS, INTRAVENOUS; KINETICS; MACROPHAGES; MICE; MICE, INBRED BALB C; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOTECHNOLOGY; PARTICLE SIZE; RIFAMPIN; SOLUBILITY; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL; TISSUE DISTRIBUTION; TUBERCULOSIS, PULMONARY;

EID: 72149131452     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.10.004     Document Type: Article

References (38)

1. Ahmad Z., Pandey R., Sharma S., and Khuller G.K. Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles. Int. J. Antimicrob. Agents 31 (2008) 142-146
2. Bajpai A.K., and Choubey J. Design of gelatin nanoparticles as swelling controlled delivery system for chloroquine phosphate. J. Mater. Sci. Mater. Med. 17 (2006) 345-358
3. Bala I., Hariharan S., and Kumar M.N. PLGA nanoparticles in drug delivery: the state of the art. Crit. Rev. Ther. Drug Carrier Syst. 21 (2004) 387-422
4. Balthasar S., Michaelis K., Dinauer N., von-Briesen H., Kreuter J., and Langer K. Preparation and characterization of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials 26 (2005) 2723-2732
5. Barrow E.W., Winchester G.A., Staas J.K., Quenelle D.C., and Barrow W.W. Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrob. Agents Chemother. 42 (1998) 2682-2689
6. Cascone M.G., Lazzeri L., Carmignani C., and Zhu Z. Gelatin nanoparticles produced by a simple W/O emulsion as delivery system for methotrexate. J. Mater. Sci. Mater. Med. 13 (2002) 523-526
7. Coester C.J., Langer K., Van-Briesen H., and Kreuter J. Gelatin nanoparticles by two-step desolvation-a new preparation method, surface modifications and cell uptake. J. Microencapsul. 17 (2000) 187-193
8. De Souza A.O., Santos-Jr R.R., Sato D.N., de Azevedo M.M.M., Ferreira D.A., Melo P.S., Celio M.H., Silva L., and Duranc N. Free 2-propen-1-amine derivative and inclusion complexes with β-cyclodextrin: scanning electron microscopy, dissolution, cytotoxicity and antimycobacterial activity. J. Braz. Chem. Soc. 15 (2004) 682-689
9. Deol P., and Khuller G.K. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim. Biophys. Acta 1334 (1997) 161-172
10. Gallo G.G., and Radaelli P. Rifampicin. In: Florey K. (Ed). Analytical Profiles of Drug Substances. Vol. 5. Indian Reprints (2005), Rajkamal Electric Press, New Delhi 469-513
11. Gaspar M.M., Cruz A., Penha A.F., Reymao J., Sousa A.C., Eleuterio C.V., Domingues S.A., Fraga A.G., Longatto Filho A., Cruz M.E.M., and Pedrosa J. Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis. Int. J. Antimicrob. Agents 31 (2008) 37-45
12. Gelperina S., Kisich K., Iseman M.D., and Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am. J. Resp. Crit. Care Med. 172 (2005) 1487-1490
13. Guillaumont M., Leclercq M., Frobert Y., and Guise B.J. Determination of rifampicin, desacetylrifampicin, isoniazid and acetylisoniazid by high-performance liquid chromatography: application to human serum extracts, polymorphonucleocytes and alveolar macrophages. Chromatogr. B: Biomed. Appl. 232 (1982) 369-376
14. Gupta U.D., and Katoch V.M. Animal models of tuberculosis for vaccine development. Indian J. Med. Res. 129 (2009) 11-18
15. Jain S.K., Gupta Y., Jain A., Saxena A.R., Khare P., and Jain A. Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomed.: Nanotechnol. Biol. Med. 4 (2008) 41-48
16. Kaul G., and Amiji M. Tumor-targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles: in vitro and in vivo studies. Pharm. Res. 22 (2005) 951-961
17. Kaur A., Jain S., and Tiwary A.K. Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: in vitro and in vivo evaluation. Acta Pharm. 58 (2008) 61-74
18. Kisich K.O., Gelperina S., Higgins M.P., Wilson S., Shipulo E., Oganesyan E., and Heifets L. Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis. Int. J. Pharm. 345 (2007) 154-162
19. Kreuter J. Nanoparticles as drug delivery system. In: Nalwa H.S. (Ed). Encyclopedia of Nanoscience and Nanotechnology, vol. 7 (2004), American Scientific Publishers, New York, USA 161-180
20. Kumar P.V., Asthana A., Dutta T., and Jain N.K. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J. Drug Target. 14 (2006) 546-556
21. Labana S., Pandey R., Sharma S., and Khuller G.K. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Int. J. Antimicrob. Agents 20 (2002) 301-304
22. Laura J.V.P., Kerstin J.W., and Vito R. Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis. J. Antimicrob. Chemother. 45 (2000) 159-165
23. Lee G.Y., Park K., Nam J.H., Kim S.Y., and Byun Y. Anti-tumor and anti-metastatic effects of gelatin-doxorubicin and PEGylated gelatin-doxorubicin nanoparticles in SCC7 bearing mice. J. Drug Target. 14 (2006) 707-716
24. Leo E., Vandelli M.A., Cameroni R., and Forni F. Doxorubicin-loaded gelatin nanoparticles stabilized by glutaraldehyde: involvement of the drug in the cross-linking process. Int. J. Pharm. 12 (1997) 75-82
25. Leo E., Cameroni R., and Forni F. Dynamic dialysis for the drug release evaluation from doxorubicin-gelatin nanoparticles conjugates. Int. J. Pharm. 180 (1999) 23-30
26. Li J.K., Wang N., and Wu X.S. Gelatin nanoencapsulation of protein/peptide drugs using an emulsifier-free emulsion method. J. Microencapsul. 15 (1998) 163-172
27. Nahar M., Mishra D., Dubey V., and Jain N.K. Development, characterization, and toxicity evaluation of amphotericin B-loaded gelatin nanoparticles. Nanomed. Nanotech. Biol. Med. 4 (2008) 252-261
28. Pandey R., and Khuller G.K. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb) 85 (2005) 227-234
29. Pandey R., and Khuller G.K. Nanoparticle-based oral drug delivery system for injectable-antibiotics streptomycin. Chemotherapy 53 (2007) 437-441
30. Pandey R., Sharma A., Zahoor A., Sharma S., Khuller G.K., and Prasad B. Poly (DL-lactide-coglycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother. 52 (2003) 981-986
31. Sharma A., Sharma S., and Khuller G.K. Lectin functionalised poly(lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J. Antimicrob. Chemother. 54 (2004) 761-766
32. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., and Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 70 (2001) 1-20
33. Toit L.C., Pillay V., and Danckwerts M.P. Tuberculosis chemotherapy: current drug delivery approaches. Resp. Res. 7 (2006) 1-18
34. Truong-Le V.L., Walsh S.M., Schweibert E., Mao H.Q., Guggino W.B., August J.T., et al. Gene transfer by DNA-gelatin nanospheres. Arch. Biochem. Biophys. 361 (1999) 47-56
35. Vandervoort J., and Ludwig A. Preparation and evaluation of drug-loaded gelatin nanoparticles for topical ophthalmic use. Eur. J. Pharm. Biopharm. 57 (2004) 251-261
36. Verma A.K., Sachin K., Saxena A., and Bohidar H.B. Release kinetics from bio-polymeric nanoparticles encapsulating protein synthesis inhibitor-cycloheximide, for possible therapeutic applications. Curr. Pharm. Biotechnol. 6 (2005) 121-130
37. World Health Organization, 2006. Global Tuberculosis Control: Surveillance, planning, financing WHO Report 2006.WHO/HTM/TB/2006.362 World Health Organization (WHO), Geneva. Available at http://www.who.int/tb/publications/global_ report/2006/en/.
38. Yeh T.K., Lu Z., Wientjes M.G., and Au J.L.S. Formulating paclitaxel in nanoparticles alters its disposition. Pharm. Res. 22 (2005) 867-874